行情

PTN

PTN

PALATIN TECH
AMEX

实时行情|Nasdaq Last Sale

0.7101
-0.0199
-2.73%
盘后: 0.7060 -0.0041 -0.58% 19:03 01/17 EST
开盘
0.7200
昨收
0.7300
最高
0.7300
最低
0.7050
成交量
67.24万
成交额
--
52周最高
1.780
52周最低
0.6551
市值
1.62亿
市盈率(TTM)
5.17
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

PTN 新闻

  • 英国央行行长称:全球经济正陷入“流动性陷阱”
  • 新浪美股.3小时前
  • 弹劾案审讯开始在即 民主党人、特朗普律师提交主张
  • 新浪财经.3小时前
  • 利比亚输油管线和谈前被关闭 或加剧石油供应中断
  • 新浪财经.4小时前
  • 使用同一"排名最低"供应商 波音777X重现MAX安全问题
  • 新浪美股.4小时前

更多

所属板块

生物技术和医学研究
-0.16%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

PTN 简况

Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The Company's primary product in clinical development is bremelanotide for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD), which is a type of female sexual dysfunction (FSD) defined as low desire with associated distress. Its other drug development programs include Melanocortin receptor-4 (MC4r), PL-3994 and Melanocortin receptor-1 (MC1r). MC4r is a compound used for treatment of obesity and diabetes. PL-3994 is a subcutaneously injected guanylate-cyclase type A (GC-A) receptor agonist. MC1r agonist peptides are used for treatment of inflammatory and dermatologic disease indications.
展开

Webull提供Palatin Technologies, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。